TL;DR
Get self-care and calm essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA has opened a 45-day public comment period on approaches for designing early-phase clinical trials of ibogaine drug products. It is seeking evidence and feedback on study populations, dosing, safety measures and independent oversight; the request does not authorize ibogaine as a treatment.
The U.S. Food and Drug Administration is seeking public input on how early-phase clinical trials of ibogaine drug products should be designed, including how researchers should select doses and monitor safety. The request opens a 45-day comment period and is intended to inform research planning; it does not establish ibogaine as an approved treatment.
In a news release dated October 5, 2026, the FDA said its request for information asks for comments, data and other material on specific clinical protocol elements. The agency is considering approaches to study design, patient eligibility, care settings, dose selection and escalation, safety monitoring, stopping rules and oversight. It said the information could help it assess potential uses, benefits and risks of ibogaine products and inform drug development.
The agency named four main areas for input: general study design and suitable patient groups; dose selection and escalation; safeguards for safety; and ethical and oversight requirements. On dosing, the FDA described a possible approach using small, sequential groups whose doses increase over time. It said a starting dose should be supported by available data and not exceed 10 milligrams per kilogram. That figure is a proposed trial-design parameter in the request, not a treatment recommendation for patients.
For safety, the FDA specifically called for consideration of monitoring for cardiac and neurologic adverse events, along with other protections in clinical trials. It also raised informed consent and independent safety oversight as issues for comment. The agency did not announce a final trial protocol or say that any particular dose, setting or patient group had been selected for a future ibogaine trial.
Comments may be submitted electronically through regulations.gov by searching for Docket No. FDA-2026-N-10429, or in writing to the FDA Dockets Management Staff in Rockville, Maryland. The release sets November 20, 2026, as the deadline and says late comments will not be considered. The agency’s notice says the period runs for 45 days following publication in the Federal Register.
Safety Questions Shape Trial Design
The request concerns how to investigate a substance for which the FDA says both scientific questions and serious safety concerns remain. Input on dose escalation, clinical setting, monitoring and stopping rules can help shape the safeguards expected in early studies. These design choices affect how researchers weigh potential signals of benefit against risks to participants, and how reliably a trial can produce evidence for later decisions.
The agency’s focus on informed consent and independent oversight also makes the request relevant to prospective participants, clinicians, researchers and organizations working on substance-related research. Public comments could bring additional data or practical concerns into the agency’s consideration. However, the request itself does not establish that ibogaine is safe or effective for any condition, and it does not authorize patients to use it as a treatment.
cardiac monitoring devices for clinical trials
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Federal Ibogaine Research Plans
The FDA described the request as its latest action tied to President Donald Trump’s April 2026 executive order on accelerating medical treatments for serious mental illness, which directed agencies to accelerate research into psychedelic medicine. In July 2026, the FDA finalized industry guidance called Psychedelic Drugs: Considerations for Clinical Investigations. The agency said that guidance offers general considerations for sponsors developing psychedelic drugs; the new request asks for input on ibogaine-specific trial questions.
The FDA also reported that it had allowed an early-phase study of noribogaine hydrochloride, an ibogaine derivative, to proceed under an Investigational New Drug application as a potential treatment for alcohol use disorder. That is a separate development involving a derivative and an early-phase study, not evidence that ibogaine itself has been approved or shown effective.
Other federal research efforts are also underway. The Department of Health and Human Services said it is supporting early-phase psychedelic research through ARPA-H, while the National Institute on Drug Abuse is funding ibogaine research for possible treatment of opioid use disorder. HHS has identified adults with opioid use disorder and adults with post-traumatic stress disorder as two initial populations for federally supported research. These priorities describe research planning, not established benefits.
“Patients facing serious conditions that have not responded to existing treatments deserve rigorous scientific investigation of promising new approaches.”
— Michael Davis, director of the FDA Center for Drug Evaluation and Research
neurologic safety monitoring equipment
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Evidence and Protocol Still Open
The FDA’s request does not resolve whether ibogaine products are safe or effective, or which conditions, if any, may ultimately benefit. The agency says it is seeking information to better understand their potential uses, benefits and risks. The release provides no results from an ibogaine efficacy trial and does not describe a completed assessment of the substance’s risks.
It is also not yet clear what final protocols the FDA may support after reviewing comments, whether the public input will lead to specific changes, or when any additional trials might begin. The agency’s proposed dose-escalation approach and 10 mg/kg ceiling are topics for input, not final requirements. The release does not detail the full set of safeguards that a particular study would use.
clinical trial safety oversight tools
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Comments Close November 20
Researchers, patients, clinicians and other stakeholders have until November 20, 2026, to send comments, data or information to the FDA docket. Submissions can address the agency’s questions on study populations, dosing, cardiac and neurologic monitoring, informed consent and independent oversight. The FDA says it will not consider late comments.
After the comment period, the agency may use the material to inform its approach to ibogaine drug development, but the release does not provide a date for a decision or promise a specific next step. Any future clinical studies would remain subject to the relevant regulatory processes and would need to generate evidence. For now, the confirmed development is a request for input—not approval of ibogaine or a finding that it treats opioid use disorder, PTSD or another condition.
ibogaine research safety monitoring
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is the FDA asking the public to comment on?
The FDA is seeking comments, data and information on early-phase ibogaine trial design, including study populations, dose selection, safety monitoring, stopping rules, informed consent and independent oversight.
Is the FDA approving ibogaine as a treatment?
No. The request is about research design and does not approve ibogaine or establish that it is safe or effective for any condition.
What dose approach does the FDA mention?
The FDA describes for public input a possible approach using small, sequential dose-ascending groups, with a starting dose justified by available data and no higher than 10 mg/kg. This is a trial-design proposal, not advice for individual use or a final protocol.
When and how can comments be submitted?
Comments are due by November 20, 2026. People can submit them at regulations.gov by searching for Docket No. FDA-2026-N-10429, or send written submissions to the FDA Dockets Management Staff in Rockville, Maryland.
What ibogaine research is already underway?
The FDA says an early-phase study of noribogaine hydrochloride, an ibogaine derivative, has been allowed to proceed under an Investigational New Drug application for potential treatment of alcohol use disorder. NIDA is also funding ibogaine research for possible treatment of opioid use disorder. These efforts do not show that ibogaine is an approved or proven treatment.
Source: primary
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
